Tirofiban without load dose in percutaneous coronary intervention for elderly patients with acute coronary syndrome
DING Li-ping
LU Cai-yi
HU Tao-hong
HU Li-hua
MA Hui-li
JIN Zhi-tao
QIU Xin-cheng
Abstract：Objective To investigate the efficacy and safety of tirofiban without load dose for elderly patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).Methods One hundred and eighty cases of ederly patients with ACS were randomly divided into tirofiban non-load group,load group and control group.The tirofiban non-load group (n =60) were given tirofiban without load dose [maintaining dose of 0.15 μg/(kg · min) iv drip for 24 h].The tirofiban load group (n =60) was given tirofiban with load dose [10 μg/kg iv within 3 min ; maintaining dose 0.15 μg/(kg · min) iv drip for 24 h].The control group (n =60)was not given tirofiban.Results Compared with the contral group during PCI,the platelet aggregation rate(PAR) was much lower when tirofian was used for 24 hours either with or without load dose [12 h:(28.6 ± 1.4)％,(32.6±3.2)％ vs (58.5±1.5)％; 24 h:(44.7±1.7)％,(46.1 ±1.9)％,vs (57.9±2.3)％,P＜0.05],the incidence of major adverse cardiac events within 30 days decreased significantly [3.3％ (2/60),1.7％ (1/60)vs 13.3％ (8/60),P ＜ 0.05].Bleeding complications were not increased significantly (P ＞ 0.05).Compared with the two subgroups using tirofiban,there was no significant difference in PAR,CK-MB,flow of the target vessel and bleeding complications.But there was a decreasing tendency of the incidence of bleeding in the treatment group without load dose.Conclusion Tirofiban without load dose is safe and effective in the treatment of elderly patients with ACS undergoing PCI.
Keywords：Coronary diseaseTirofibanAngioplastytransluminalpercutaneous coronary
Publication Date：2013-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 7-9 )